#LAMA LABA COPD TRIAL#
#LAMA LABA COPD PLUS#

“This is the second trial to show a benefit of triple therapy over dual therapy with LAMA/LABA with respect to mortality among patients with COPD,” investigators wrote.

#LAMA LABA COPD PLUS#

002).Ī lower mortality rate was observed in patients with COPD treated with 320 mcg budesonide plus LAMA/LABA versus those treated with dual therapy.

Lower-dose budesonide (160 mcg) plus LAMA/LABA was also associated with similar, significantly reduced annual exacerbations than LAMA/LABA (RR, 0.75 95% CI, 0.69-0.83 P <.001) and ICS/LABA (RR, 0.86 95% CI, 0.79-0.95 P =. The 13% reduction between this treatment arm and patients on ICS/LABA was also deemed significant (RR, 0.87 95% CI, 0.79-0.95 P =. They confirmed that exacerbation rates were significantly lower with 320 mcg budesonide plus LAMA/LABA than with LAMA/LABA-a 24% reduction (RR, 0.76 95% CI, 0.69-0.83 P <.001). Among patients treated with LAMA/LABA or ICS/LABA, annual exacerbations were 1.42 and 1.24, respectively. Investigators observed annual moderate or severe exacerbation rates of 1.08 and 1.07 in patients treated with 320 mcg and 160 mcg budesonide plus LAMA/LABA, respectively. Mean patient age in all treatment arms was 64.6☗.6, with approximately three-fifths of patients being male. George’s Respiratory Questionnaire (SGRQ) response, and time to death from any cause. Secondary endpoints included time to first exacerbation, change from baseline in average daily rescue medication use over 24 weeks, rate of patients with a St. Rabe and colleagues sought a primary endpoint of annual rate of moderate or severe exacerbations, as per mean number per patient per year, as analyzed in the modified intention-to-treat population with the use of on-treatment data only. Patients administered budesonide in the dual therapy treatment arm were given 320 mcg.ĭoses were administered twice daily over a 52-week period. Patients were randomized 1:1:1:1 to either twice-daily inhaled doses of the triple therapy (160 or 320 mcg budesonide/ 18 mcg glycopyrrolate/ 9.6 mcg formoterol), or one of the 2 dual therapy options. Their patient population included 8509 patients aged 40-80 years old with moderate to very severe COPD and at least 1 exacerbation in the last year.

Rabe, MD, of the Airway Research Center North in Germany, conducted the 52-week, phase 3, randomized trial funded by AstraZeneca. The findings, presented during the American Thoracic Society (ATS) 2020 Virtual Sessions, show benefit of inhaled corticosteroid (ICS) plus LAMA/LABA pertain to quality of life and mortality metrics in patients with COPD, as well as that of exacerbation rates. In new results from the Efficacy and Safety of Triple Therapy in Obstructive Lung Disease (ETHOS) trial, investigators reported results showed a fixed dose of either 160 or 320 mcg inhaled budesonide with long-acting meta antagonist (LAMA) glycopyrrolate plus long-acting beta agonist (LABA) formoterol reduced COPD exacerbations over 52 weeks at a notably greater rate than glycopyrrolate-formoterol or budesonide-formoterol. Twice-daily budesonide/glycopyrrolate/formoterol significantly lowered exacerbations in patients with moderate or severe chronic obstructive pulmonary disease (COPD) versus a pair of double therapy inhalers, according to new findings.

Lama laba copd